Genedit

Genedit company information, Employees & Contact Information

Explore related pages

Related company profiles:

GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Company Details

Employees
55
Founded
-
Address
681 Gateway Blvd,
Email
pa****@****dit.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Genedit employee's phone or email?

Genedit Questions

News

GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology - Business Wire

GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology Business Wire

Korean scientist inspired by the ‘Genentech story’ brings technology to Genentech, making a dream come true - 더바이오

Korean scientist inspired by the ‘Genentech story’ brings technology to Genentech, making a dream come true 더바이오

Press Release Service: GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease - CRISPR Medicine News

Press Release Service: GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease CRISPR Medicine News

GenEdit raises $24M, signs Genentech deal - Chemical & Engineering News

GenEdit raises $24M, signs Genentech deal Chemical & Engineering News

GenEdit Tackles "Delivery, Delivery, Delivery" with Up-to-$644M Genentech Collaboration - Genetic Engineering and Biotechnology News

GenEdit Tackles "Delivery, Delivery, Delivery" with Up-to-$644M Genentech Collaboration Genetic Engineering and Biotechnology News

Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology

Genentech signs nanoparticle deal worth up to $644m with GenEdit Pharmaceutical Technology

Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy - Fierce Biotech

Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy Fierce Biotech

Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods - BioPharma Dive

Sarepta reveals gene editing alliance with biotech exploring alternative delivery methods BioPharma Dive

Roche’s Genentech and GenEdit enter autoimmune disease partnership worth up to $644m - PMLiVE

Roche’s Genentech and GenEdit enter autoimmune disease partnership worth up to $644m PMLiVE

GenEdit Secures $35 Million in Series B Funding, Aims to Lead Gene Therapy - 동아사이언스

GenEdit Secures $35 Million in Series B Funding, Aims to Lead Gene Therapy 동아사이언스

KIMCo jointly invests $1.7 mil. in US biotech firm GenEdit - koreabiomed.com

KIMCo jointly invests $1.7 mil. in US biotech firm GenEdit koreabiomed.com

GenEdit strikes Eli Lilly gold with $26M for gene therapy delivery system designed to fight side effects - Fierce Biotech

GenEdit strikes Eli Lilly gold with $26M for gene therapy delivery system designed to fight side effects Fierce Biotech

On the 23rd, Silicon Valley-based genetic drug development startup "GENEDIT" announced that it will - 매일경제

On the 23rd, Silicon Valley-based genetic drug development startup "GENEDIT" announced that it will 매일경제

Sarepta rushes for GenEdit's polymer nanoparticles in $57M gene editing delivery partnership - Fierce Biotech

Sarepta rushes for GenEdit's polymer nanoparticles in $57M gene editing delivery partnership Fierce Biotech

GenEdit reels in $8.5M to tackle delivery for gene therapy, gene editing - Fierce Biotech

GenEdit reels in $8.5M to tackle delivery for gene therapy, gene editing Fierce Biotech

Top Genedit Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant